REDWOOD CITY, Calif. – May 27, 2014 – PaxVax Inc., a specialty vaccine company with a commercial focus on travel and biodefense and a social mission to ensure global access to its vaccines, today announced that company Chief Executive Officer Ken Kelley will present at the Jefferies 2014 Global Healthcare Conference in New York City on Tuesday, June 3 at 10:00 a.m. EDT. A breakout session will follow at 10:30 a.m. EDT.
“PaxVax is entering a new phase of growth that is built on the rapid and late-stage progress of our lead vaccine candidate, PXVX0200. This oral, single-dose, attenuated cholera vaccine, which is currently in Phase 3 clinical trials, is designed to protect international travelers from cholera,” said Kelley. “I am looking forward to discussing our progress in more detail at the Jefferies meeting.”
The U.S. Food and Drug Administration has granted the company’s cholera vaccine candidate Fast Track designation in response to the lack of an available U.S. vaccine against this infectious disease. PaxVax’s clinical pipeline also includes a pandemic oral vectored H5N1 influenza vaccine, which recently concluded a successful Phase 1 clinical trial, as well as two oral vectored vaccines for anthrax, which are currently in Phase 1 clinical trials in collaboration with the U.S. National Institutes of Health (NIH). The company also has a pipeline of early-stage travel vaccine candidates for dengue, malaria and rabies.
PaxVax has raised nearly $75 million from investors including Ignition Partners and Blue Haven Initiative. The company is also supported by grants, contracts, and awards from the NIH through the National Institute of Allergy and Infectious Diseases (NIAID), its Division of Acquired Immunodeficiency Syndrome (DAIDS) and its Division of Microbiology and Infectious Diseases (DMID), as well as the Wellcome Trust and the Bill and Melinda Gates Foundation.
Founded in 2007, PaxVax is a privately held specialty vaccine company focused on developing effective vaccines for travel and biodefense. PaxVax’s clinical-stage portfolio includes its lead product PXVX0200, which is an oral, single-dose cholera vaccine in Phase 3 clinical trials, a pandemic oral vectored H5N1 influenza vaccine that recently concluded a successful Phase 1 clinical trial, as well as an oral vectored vaccine for anthrax, which is currently in Phase 1 clinical trials in collaboration with the U.S. National Institutes of Health. The company’s proprietary adenoviral-based technology platform enables the rapid development of oral vaccines that can target any viral or bacterial protein antigen. PaxVax’s vaccine candidates are designed to enhance the desired immune response and offer an easier way to manufacture, store, distribute, administer, and deliver vaccines across the globe compared to conventional injectable vaccines. PaxVax is headquartered in Redwood City, California and has research and development laboratories and state-licensed Good Manufacturing Practice (GMP) facilities in San Diego, California. More information about PaxVax is available at www.PaxVax.com.Download Press Release